JP2004529911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529911A5 JP2004529911A5 JP2002576189A JP2002576189A JP2004529911A5 JP 2004529911 A5 JP2004529911 A5 JP 2004529911A5 JP 2002576189 A JP2002576189 A JP 2002576189A JP 2002576189 A JP2002576189 A JP 2002576189A JP 2004529911 A5 JP2004529911 A5 JP 2004529911A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- prodrug
- compound
- substituted
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000000651 prodrug Substances 0.000 claims 22
- 229940002612 prodrug Drugs 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 229910004013 NO 2 Inorganic materials 0.000 claims 5
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- -1 cyano, carboxy Chemical group 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 102400000068 Angiostatin Human genes 0.000 claims 2
- 108010079709 Angiostatins Proteins 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102400001047 Endostatin Human genes 0.000 claims 2
- 108010079505 Endostatins Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 102000004211 Platelet factor 4 Human genes 0.000 claims 2
- 108090000778 Platelet factor 4 Proteins 0.000 claims 2
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims 2
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000001772 anti-angiogenic effect Effects 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 239000013059 antihormonal agent Substances 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 2
- 229950009003 cilengitide Drugs 0.000 claims 2
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229930014626 natural product Natural products 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 229950001248 squalamine Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims 2
- 229960005314 suramin Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940063683 taxotere Drugs 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 2
- 229950000578 vatalanib Drugs 0.000 claims 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000000982 vasogenic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26595101P | 2001-02-02 | 2001-02-02 | |
| PCT/US2002/002888 WO2002076926A1 (en) | 2001-02-02 | 2002-02-01 | 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529911A JP2004529911A (ja) | 2004-09-30 |
| JP2004529911A5 true JP2004529911A5 (enExample) | 2005-12-22 |
Family
ID=23012553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002576189A Pending JP2004529911A (ja) | 2001-02-02 | 2002-02-01 | Ｃｘｃケモカインレセプターアンタゴニストとしての３，４−二置換シクロブテン−１，２−ジオン |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20030097004A1 (enExample) |
| EP (1) | EP1355875A1 (enExample) |
| JP (1) | JP2004529911A (enExample) |
| KR (1) | KR20030090629A (enExample) |
| CN (1) | CN1575273A (enExample) |
| AU (1) | AU2002303084B2 (enExample) |
| BR (1) | BR0206968A (enExample) |
| CA (1) | CA2436351A1 (enExample) |
| CZ (1) | CZ20032098A3 (enExample) |
| EC (1) | ECSP034712A (enExample) |
| HU (1) | HUP0304047A2 (enExample) |
| IL (1) | IL156793A0 (enExample) |
| MX (1) | MXPA03006950A (enExample) |
| NO (1) | NO20033424L (enExample) |
| NZ (1) | NZ527947A (enExample) |
| PL (1) | PL367534A1 (enExample) |
| RU (1) | RU2003126913A (enExample) |
| SK (1) | SK9782003A3 (enExample) |
| WO (1) | WO2002076926A1 (enExample) |
| ZA (1) | ZA200305881B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037916B2 (en) * | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7475478B2 (en) | 2001-06-29 | 2009-01-13 | Kva, Inc. | Method for manufacturing automotive structural members |
| CN1599734A (zh) | 2001-10-12 | 2005-03-23 | 先灵公司 | 作为cxc趋化因子受体拮抗剂的3,4－二取代的马来酰亚胺化合物 |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| WO2003080053A1 (en) | 2002-03-18 | 2003-10-02 | Schering Corporation | Combination treatments for chemokine-mediated diseases |
| WO2003099223A2 (en) * | 2002-05-24 | 2003-12-04 | The Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
| JP4743382B2 (ja) | 2002-06-06 | 2011-08-10 | 株式会社医薬分子設計研究所 | Ｏ−置換ヒドロキシアリール誘導体 |
| BR0312283A (pt) | 2002-06-28 | 2005-04-12 | Novartis Ag | Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf |
| EP1551818B1 (en) | 2002-10-09 | 2009-02-04 | Schering Corporation | Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands |
| TW200418812A (en) * | 2002-10-29 | 2004-10-01 | Smithkline Beecham Corp | IL-8 receptor antagonists |
| JP2006508950A (ja) * | 2002-10-31 | 2006-03-16 | セルジーン・コーポレーション | 黄斑変性の治療用組成物 |
| WO2004069829A1 (en) * | 2003-01-10 | 2004-08-19 | Pharmacopeia Drug Discovery, Inc. | (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis |
| CN100448860C (zh) * | 2003-04-18 | 2009-01-07 | 先灵公司 | 合成2－羟基－n,n－二甲基－3－[[2－[[1(r)－(5－甲基－2－呋喃基)丙基]氨基]－3,4－二氧代－1－环丁烯－1－基]氨基]苯甲酰胺 |
| RU2006104697A (ru) * | 2003-07-16 | 2006-06-27 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. (Jp) | Лекарственное средство для лечения пигментации кожи |
| DE602004016211D1 (en) * | 2003-12-19 | 2008-10-09 | Schering Corp | Thiadiazole als cxc- und cc-chemokinrezeptorliganden |
| WO2005068460A1 (en) | 2003-12-22 | 2005-07-28 | Schering Corporation | Isothiazole dioxides as cxc- and cc- chemokine receptor ligands |
| WO2005113534A2 (en) | 2004-05-12 | 2005-12-01 | Schering Corporation | Cxcr1 and cxcr2 chemokine antagonists |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| ES2327840T3 (es) * | 2004-12-23 | 2009-11-04 | Gpc Biotech Ag | Derivados de acido escuarico con actividad antiproliferativa. |
| DE102005001053A1 (de) * | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Quadratsäurederivate |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| AU2006223070B2 (en) * | 2005-03-14 | 2012-02-09 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| US7718678B2 (en) | 2005-06-29 | 2010-05-18 | Schering Corporation | Di-substituted oxadiazoles as CXC-chemokine receptor ligands |
| DE602006017849D1 (de) | 2005-06-29 | 2010-12-09 | Schering Corp | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors |
| DE102005035741A1 (de) * | 2005-07-29 | 2007-02-08 | Merck Patent Gmbh | Quadratsäurederivate |
| DE102005035742A1 (de) * | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| JP2009523734A (ja) | 2006-01-13 | 2009-06-25 | ワイス | ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール |
| BRPI0710559A2 (pt) * | 2006-04-21 | 2011-08-16 | Smithkline Beecham Corp | antagonistas de receptores de il-8 |
| DK2009992T3 (da) * | 2006-04-21 | 2012-08-13 | Glaxosmithkline Llc | Il-8 receptor-antagonister |
| CN101448778A (zh) * | 2006-05-26 | 2009-06-03 | 艾博特公司 | Polo样激酶的抑制剂 |
| US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
| AR061571A1 (es) * | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un |
| US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| WO2010131146A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| WO2011036280A1 (en) | 2009-09-28 | 2011-03-31 | F. Hoffmann-La Roche Ag | Benzoxazepin pi3k inhibitor compounds and methods of use |
| CA2799154A1 (en) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Indazole inhibitors of kinase |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| RU2020106383A (ru) * | 2017-08-14 | 2021-09-16 | Аллерган, Инк. | 3,4-двузамещенные 3-циклобутен-1,2-дионы и их применение |
| IL275839B2 (en) | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
| CN108660203A (zh) * | 2018-05-18 | 2018-10-16 | 大连医科大学附属第医院 | Cxcr2基因在心脏相关疾病中的用途 |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN112851635B (zh) * | 2019-11-28 | 2022-09-16 | 中国医学科学院药物研究所 | 环状砜类化合物及其制备方法、用途和药物组合物 |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1531943A (fr) * | 1966-07-28 | 1968-07-05 | Huels Chemische Werke Ag | Procédé pour stabiliser des poly-acétals macromoléculaires |
| DE2638855C3 (de) * | 1976-08-28 | 1980-04-24 | Chemische Werke Huels Ag, 4370 Marl | Verwendung von Quadratsäureamiden als Stabilisierungsmittel für geformte oder nicht geformte Kunststoffe |
| US5466712A (en) * | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5849403A (en) * | 1995-09-13 | 1998-12-15 | Kabushiki Kaisha Toshiba | Organic thin film device |
| US6150042A (en) * | 1996-12-09 | 2000-11-21 | Toyo Ink Manufacturing Co., Ltd. | Material for organoelectro-luminescence device and use thereof |
| US5840764A (en) * | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| US6303238B1 (en) * | 1997-12-01 | 2001-10-16 | The Trustees Of Princeton University | OLEDs doped with phosphorescent compounds |
| JP2998737B2 (ja) * | 1998-03-13 | 2000-01-11 | 日本電気株式会社 | 周辺機器用電源制御装置 |
| WO2000014174A1 (en) * | 1998-09-09 | 2000-03-16 | Idemitsu Kosan Co., Ltd. | Organic electroluminescence device and phenylenediamine derivative |
| ATE224358T1 (de) * | 1998-10-02 | 2002-10-15 | Neurosearch As | Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung |
| ID30235A (id) * | 1998-12-16 | 2001-11-15 | Bayer Ag | Senyawa bifenil dan analognya sebagai antagonis-antagonis integrin |
| JP3924648B2 (ja) * | 1999-11-02 | 2007-06-06 | ソニー株式会社 | 有機電界発光素子 |
| AU3056301A (en) * | 2000-02-02 | 2001-08-14 | Mitsubishi Chemical Corporation | Organic electroluminescent element and method of manufacture thereof |
| AR033803A1 (es) * | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| KR20010104215A (ko) * | 2000-05-12 | 2001-11-24 | 야마자끼 순페이 | 발광장치 제작방법 |
| CN1454204A (zh) * | 2000-05-30 | 2003-11-05 | 史密丝克莱恩比彻姆公司 | Il－8受体拮抗剂 |
| TW545080B (en) * | 2000-12-28 | 2003-08-01 | Semiconductor Energy Lab | Light emitting device and method of manufacturing the same |
| SG138466A1 (en) * | 2000-12-28 | 2008-01-28 | Semiconductor Energy Lab | Luminescent device |
| WO2002067919A1 (en) * | 2001-01-16 | 2002-09-06 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| TW518909B (en) * | 2001-01-17 | 2003-01-21 | Semiconductor Energy Lab | Luminescent device and method of manufacturing same |
| TW519770B (en) * | 2001-01-18 | 2003-02-01 | Semiconductor Energy Lab | Light emitting device and manufacturing method thereof |
| US6765348B2 (en) * | 2001-01-26 | 2004-07-20 | Xerox Corporation | Electroluminescent devices containing thermal protective layers |
| SG118110A1 (en) * | 2001-02-01 | 2006-01-27 | Semiconductor Energy Lab | Organic light emitting element and display device using the element |
| US20030010288A1 (en) * | 2001-02-08 | 2003-01-16 | Shunpei Yamazaki | Film formation apparatus and film formation method |
| TW582121B (en) * | 2001-02-08 | 2004-04-01 | Semiconductor Energy Lab | Light emitting device |
| TW550672B (en) * | 2001-02-21 | 2003-09-01 | Semiconductor Energy Lab | Method and apparatus for film deposition |
| SG118118A1 (en) * | 2001-02-22 | 2006-01-27 | Semiconductor Energy Lab | Organic light emitting device and display using the same |
-
2002
- 2002-02-01 IL IL15679302A patent/IL156793A0/xx unknown
- 2002-02-01 JP JP2002576189A patent/JP2004529911A/ja active Pending
- 2002-02-01 EP EP02731085A patent/EP1355875A1/en not_active Withdrawn
- 2002-02-01 PL PL02367534A patent/PL367534A1/xx not_active Application Discontinuation
- 2002-02-01 CZ CZ20032098A patent/CZ20032098A3/cs unknown
- 2002-02-01 CN CNA028045173A patent/CN1575273A/zh active Pending
- 2002-02-01 US US10/062,006 patent/US20030097004A1/en not_active Abandoned
- 2002-02-01 SK SK978-2003A patent/SK9782003A3/sk not_active Application Discontinuation
- 2002-02-01 AU AU2002303084A patent/AU2002303084B2/en not_active Ceased
- 2002-02-01 KR KR10-2003-7009958A patent/KR20030090629A/ko not_active Ceased
- 2002-02-01 CA CA002436351A patent/CA2436351A1/en not_active Abandoned
- 2002-02-01 BR BR0206968-7A patent/BR0206968A/pt not_active IP Right Cessation
- 2002-02-01 HU HU0304047A patent/HUP0304047A2/hu unknown
- 2002-02-01 WO PCT/US2002/002888 patent/WO2002076926A1/en not_active Ceased
- 2002-02-01 MX MXPA03006950A patent/MXPA03006950A/es not_active Application Discontinuation
- 2002-02-01 NZ NZ527947A patent/NZ527947A/en unknown
- 2002-02-01 RU RU2003126913/04A patent/RU2003126913A/ru not_active Application Discontinuation
-
2003
- 2003-07-30 ZA ZA2003/05881A patent/ZA200305881B/en unknown
- 2003-07-31 NO NO20033424A patent/NO20033424L/no not_active Application Discontinuation
- 2003-08-01 EC EC2003004712A patent/ECSP034712A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004529911A5 (enExample) | ||
| RU2003126913A (ru) | 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс | |
| TWI699359B (zh) | ４ｈ-吡咯［３,２-ｃ］吡啶-４-酮衍生物 | |
| JP2004532846A5 (enExample) | ||
| JP5643312B2 (ja) | カリウムイオンチャネルインヒビターとしてのキナゾリン | |
| JP2020158523A (ja) | 新規ヒストンデアセチラーゼインヒビター | |
| US11304946B2 (en) | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | |
| US11690911B2 (en) | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors | |
| JP2016522246A5 (enExample) | ||
| CA2952307A1 (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
| JP2019094345A5 (enExample) | ||
| JP2003512353A5 (enExample) | ||
| JP2016505042A5 (enExample) | ||
| JP2020527588A5 (enExample) | ||
| JP2015533782A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2008500336A5 (enExample) | ||
| CN116531380A (zh) | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 | |
| CN102548965A (zh) | 取代酰胺化合物 | |
| JP2019502691A5 (enExample) | ||
| RU2003131693A (ru) | Новые ингибиторы тирозин киназ | |
| JP2009536196A5 (enExample) | ||
| JPWO2008007780A1 (ja) | ペンタジエナミド誘導体 | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| TW201718534A (zh) | ３－胺基－１，５，６，７－四氫－４ｈ－吲哚－４－酮 | |
| AU2015338946B2 (en) | Potent gamma-secretase modulators |